Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pharmacogenomics of GLP1 Receptor Agonists
NCT05762744 · University of Maryland, Baltimore · PHASE1 · terminated · last registry update 2025-07-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “We concluded that it would not be possible to meet our recruitment targets within the available budget. The study was ended when the funding ended.” | – | Registry record, University of Maryland, Baltimore |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GLP1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-26Phase 3 first posted: McMaster University, Tirzepatide (NCT07671248)
- 2026-06-25Phase 3 first posted: Eli Lilly and Company, Orforglipron + Dulaglutide (NCT07668336)
- 2026-06-25Phase 3 first posted: Novo Nordisk A/S, Zenagamtide + Semaglutide (NCT07668414)
- 2026-06-23Phase 3 first posted: AstraZeneca, Elecoglipron + Semaglutide (NCT07662213)
- 2026-06-17Phase 3 first posted: The United Bio-Technology (Hengqin) Co., Ltd., UBT251 Injection 2.0 mg group + UBT251 Injection 4.0 mg group (NCT07653477)
- 2026-06-09Phase 3 first posted: Sun Yat-sen University, Group A (triple combination intensive therapy group) + Group B (standard therapy group) (NCT07635953)
- 2026-06-05Phase 3 first posted: Carnot Laboratories, Bofanglutide + Semaglutide (NCT07628985)
- 2026-06-03Phase 3 first posted: Carnot Laboratories, Bofanglutida + Semaglutide (NCT07622810)
- 2026-06-03Results posted on the registry: Novo Nordisk A/S, Insulin Icodec + Semaglutide (NCT05813912)
- 2026-05-04Phase 3 first posted: Novo Nordisk A/S, Cagrisema + Semaglutide (NCT07564414)
- 2026-02-24Results posted on the registry: Novo Nordisk A/S, Semaglutide + Placebo (NCT05891496)
- 2026-02-24Phase 3 first posted: Emory University, Semaglutide (NCT07428746)
- 2026-02-17Results posted on the registry: Case Western Reserve University, Semaglutide Injectable Product + Placebo (NCT04019197)
- 2026-02-10Phase 3 first posted: Novo Nordisk A/S, NNC0487-0111 + Semaglutide (NCT07400107)
- 2026-01-22Phase 3 first posted: Novo Nordisk A/S, Cagrisema + Placebo CagriSema (NCT07357766)
- 2026-01-22Phase 3 first posted: Eli Lilly and Company, Retatrutide (NCT07357415)
- 2025-12-19Phase 3 first posted: Instituto Mexicano del Seguro Social, Dapagliflozin 10 MG Oral Tablet + Semaglutide (Rybelsus®) (NCT07295223)
- 2025-12-16Phase 3 first posted: Kailera, Ribupatide + Semaglutide (NCT07284979)
- 2025-12-16Phase 3 first posted: McGill University Health Centre/Research Institute of the McGill University Health Centre, Tirzepatide (NCT07284511)
- 2025-12-15Phase 3 first posted: Novo Nordisk A/S, CagriSema (Cagrilintide B and Semaglutide I) + Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) (NCT07282613)
- 2025-12-09Phase 3 first posted: Novo Nordisk A/S, Oral semaglutide (NCT07271251)
- 2025-11-28Phase 3 first posted: Novo Nordisk A/S, Cagrilintide + Semaglutide (NCT07253285)
- 2025-11-18Phase 3 first posted: Eli Lilly and Company, Retatrutide + Placebo (NCT07232719)
- 2025-10-20Phase 3 first posted: VA Office of Research and Development, Semaglutide + Placebo (NCT07218354)
- 2025-09-10Phase 3 first posted: Eli Lilly and Company, Tirzepatide + Retatrutide (NCT07165028)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision